跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Hydroxyfasudil
首页
药物
Hydroxyfasudil
Experimental
Small Molecule
Hydroxyfasudil
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
技术标识符
化学式
C
14
H
17
N
3
O
3
S
CAS 编号
105628-72-6
UNII ID
EYH4AU7P63
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Preparing method of hydroxyfasudil semihydrate
申请人: SHANDONG XINHUA PHARMACEUTICAL
优先权: 2019
CN
Preparation method of high-purity hydroxyfasudil
申请人: ZHENGZHOU SIHUAN MEDICINE ARTICLE CO LTD
优先权: 2014
CN
Medicine hydroxyfasudil composition granula for treating cerebral ischemia
申请人: QINGDAO HUAZHICAO PHARMACEUTICAL CO LTD
优先权: 2015
CN
Hydroxyfasudil composition dry suspension for treating ischemic cerebrovascular diseases
申请人: QINGDAO LANSHENGYANG MEDICAL BIOLOG TECHNOLOGY CO LTD
优先权: 2015
CN
Medicine for treating cerebral ischemia
申请人: ZHANG XIAOFENG
优先权: 2015
CN
METHOD OF TREATING PATIENTS WITH NOTCH3 MUTATIONS
申请人: WOOLSEY PHARMACEUTICALS INC
优先权: 2023
CN
WO
2 件公开
METHODS OF TREATING SPORADIC CEREBRAL SMALL VESSEL DISEASE
申请人: WOOLSEY PHARMACEUTICALS INC
优先权: 2023
WO
Treatment of sickle cell disease
申请人: ESSACK MAGBUBAH
优先权: 2012
US
3 件公开
药物
反馈